Pieris Pharmaceuticals Inc (PIRS)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile

Pieris Pharmaceuticals Inc

857-246-8998

225 FRANKLIN STREET, BOSTON, MA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

PIRS's Discussions on Twitter

Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-03-13	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-07-30	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-05-14	Eingeleitet	Robert W. Baird	Outperform
2018-03-19	Eingeleitet	Evercore ISI	Outperform
2018-03-19	Eingeleitet	Jefferies	Buy
2018-01-16	Bestätigt	H.C. Wainwright	Buy
2017-05-30	Eingeleitet	Rodman & Renshaw	Buy
2016-08-05	Fortgesetzt	ROTH Capital	Buy
2015-08-12	Eingeleitet	JMP Securities	Mkt Outperform
2015-07-27	Eingeleitet	Oppenheimer	Outperform
2015-07-22	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Pieris Pharmaceuticals Inc Aktie (PIRS) Neueste Nachrichten

Finanzdaten der Pieris Pharmaceuticals Inc-Aktie (PIRS)

Pieris Pharmaceuticals Inc-Aktie (PIRS) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
ADAR1 Capital Management, LLC	10% Owner	Aug 09 '24	Buy	14.89	3,000	44,679	127,331

Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals Inc Stock (PIRS) Company Profile

Pieris Pharmaceuticals Inc Stock (PIRS) Upgrades & Downgrades

Pieris Pharmaceuticals Inc Aktie (PIRS) Neueste Nachrichten

How the (PIRS) price action is used to our Advantage - Stock Traders Daily

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire

(PIRS) Investment Analysis and Advice - Stock Traders Daily

Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today

Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance

We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire

Pieris Pharmaceuticals: Q2 Earnings Snapshot - San Antonio Express-News

Pieris Pharmaceuticals: Q2 Earnings Snapshot - mySA

Pieris Pharmaceuticals: Q2 Earnings Snapshot - CTPost

Pieris Pharmaceuticals: Q2 Earnings Snapshot - The Advocate

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World

Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com

(PIRS) Long Term Investment Analysis - Stock Traders Daily

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World

Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News

PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Manchestertimes

Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - Morningstar

General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Business Wire

Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal

Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal

Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal

Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire

Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga

PIRS Stock on the Rise: A Promising Investment - The InvestChronicle

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga

Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga

Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace

Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble

Palvella and Pieris to merge - The Pharma Letter

Pieris Pharma stock surges on merger deal (NASDAQ:PIRS) - Seeking Alpha

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $9.25 - Defense World

Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics - MarketWatch

Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading - Stocks Telegraph

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Yahoo Finance

Troutman Pepper Advises Palvella Therapeutics in Merger with Pieris Pharmaceuticals - Troutman Pepper

MEIP Stock sees a Significant Surge Amidst Strategic Evaluation - BP Journal

(PIRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily

StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - American Banking and Market News

StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World

The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30% - Simply Wall St

(PIRS) Technical Pivots with Risk Controls - Stock Traders Daily

Pieris loses Servier as partner for cancer immunotherapies - pharmaphorum

Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com - Defense World

Pieris Pharma Says Servier Discontinues License Agreement - MarketWatch

Finanzdaten der Pieris Pharmaceuticals Inc-Aktie (PIRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Pieris Pharmaceuticals Inc-Aktie (PIRS) Insiderhandel

Ähnlich wie PIRS